Ironwood Pharmaceuticals. has filed a patent for delayed release pharmaceutical compositions containing linaclotide or its salts. The invention covers methods for preparation and use of these compositions. GlobalData’s report on Ironwood Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ironwood Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ironwood Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Ironwood Pharmaceuticals's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

Delayed release pharmaceutical composition containing linaclotide

Source: United States Patent and Trademark Office (USPTO). Credit: Ironwood Pharmaceuticals Inc

A delayed release pharmaceutical composition comprising linaclotide or a pharmaceutically acceptable salt thereof is the subject of a recently filed patent (Publication Number: US20230398173A1). The composition can be in the form of a delayed release tablet or capsule, with the option of including an enteric or functional coating for added protection. The composition is designed to release at least 70% or 80% of the linaclotide at a pH greater than 5 or 7, with a disintegration rate of less than 30 seconds at the specified pH levels. Additionally, the composition aims to release linaclotide in specific regions of the gastrointestinal tract, such as the ileum, terminal ileum, or colon, for targeted therapeutic effects.

Furthermore, the patent claims encompass various formulations involving polymers, stabilizing agents, and cations to enhance the efficacy and stability of the composition. The inclusion of specific amino acids, such as histidine, and divalent metal cations like calcium or magnesium, in precise molar ratios further highlights the meticulous design of the pharmaceutical composition. The patent also covers methods of manufacturing the composition, unit dosage forms, and applications in treating gastrointestinal disorders like irritable bowel syndrome, constipation, and other related conditions. Overall, the patent outlines a comprehensive approach to developing a novel delayed release pharmaceutical composition for targeted delivery and treatment of gastrointestinal ailments.

To know more about GlobalData’s detailed insights on Ironwood Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies